Clinical Complications of HIV and Its Therapy

Faculty:

Andrew Carr, MBBS, MD, FRACP, FRCP Donald P. Kotler, MD Bruce Polsky, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Summarize data concerning the cardiovascular, renal, metabolic, and neurologic complications associated with HIV and antiretroviral therapy
• Discuss issues regarding the management of patients with HIV and coinfected with hepatitis B virus, human papillomavirus, or tuberculosis
• Describe complications specific to certain HIV-infected populations such as women and men who have sex with men
• Explain the efficacy and safety results associated with the use of abacavir/lamivudine vs tenofovir/emtricitabine in treatment-naive patients.

Topics covered include:

• Association Between Abacavir Use and Risk for Cardiovascular Events
• No Effect on Lipohypertrophy With Switch From Boosted PI to Boosted Atazanavir
• Improvement in Limb Fat With a Switch From Zidovudine/Lamivudine to Emtricitabine/Tenofovir
• Risk Factors for Nevirapine Toxicity
• Relationship Between Tenofovir and Renal Dysfunction
• Low Bone Mineral Density Among HIV-Uninfected Men Who Have Sex With Men
• Limitations of Transient Elastography for Liver Fibrosis Determination
• Occult HBV Infection in the Setting of HIV Infection
• Pregabalin for Treatment of Peripheral Neuropathy
• Health-Related Issues in HIV-Infected Women
• Relationships Between Tuberculosis and HAART
• Concluding Remarks